FRCPC

South Carolina is the First state in 2023 to be “SUNucated”

Retrieved on: 
Wednesday, May 17, 2023
Life, Curriculum, Skin cancer, Dermatology, School, Personal protective equipment, Student, American Society of Interventional Pain Physicians, Federal Food, Drug, and Cosmetic Act, MD, Risk, Weather, FRCPC, Society, Legislation, Nursing

The law, signed by Governor Henry McMaster, also enables children to wear protective clothing and allows schools to teach students sun safety curriculum.

Key Points: 
  • The law, signed by Governor Henry McMaster, also enables children to wear protective clothing and allows schools to teach students sun safety curriculum.
  • South Carolina is the 27th state to adopt model legislation that is the foundation of the SUNucate initiative developed by the American Society for Dematologic Surgery Association (ASDSA) to address barriers to sunscreen use in school and camps and promotes sun-safe behaviors.
  • “I congratulate South Carolina on passing this critical common-sense legislation to instill sun-safe habits and protect children from overexposure to the sun,” said ASDSA President Vince Bertucci, MD, FRCPC.
  • Sunscreens are regulated as over-the-counter drugs under the Federal Food, Drug and Cosmetic Act, making them subject to these bans.

AACE Releases 2023 Type 2 Diabetes Management Algorithm to Support Clinical Decision Making

Retrieved on: 
Friday, May 5, 2023
Heart, Endocrine Practice, Type 2 diabetes, Kidney failure, Obesity, Diabetes, Vaccination, Public, FACE, AACE, Health equity, Quality of life, CDC, Patient, Map, Korea Disease Control and Prevention Agency, Overweight, American Association of Clinical Endocrinologists, FRCPC, Health, Prediabetes, Samson, Environment, Nursing, T2D

JACKSONVILLE, Fla., May 5, 2023 /PRNewswire/ -- Today, the American Association of Clinical Endocrinology (AACE) announced the publication of the 2023 Comprehensive Type 2 Diabetes Management Algorithm, which provides concise guidance to assist healthcare professionals in clinical decision-making for the management of Type 2 diabetes (T2D). The algorithm, which was unveiled at the AACE Annual Meeting in Seattle, builds on previous versions to include the most recent evidence-based recommendations for the care and treatment of T2D. The updated algorithm incorporates a person-centered approach to care with a greater emphasis on associated conditions, complications and health equity.

Key Points: 
  • JACKSONVILLE, Fla., May 5, 2023 /PRNewswire/ -- Today, the American Association of Clinical Endocrinology (AACE) announced the publication of the 2023 Comprehensive Type 2 Diabetes Management Algorithm , which provides concise guidance to assist healthcare professionals in clinical decision-making for the management of Type 2 diabetes (T2D).
  • The updated algorithm incorporates a person-centered approach to care with a greater emphasis on associated conditions, complications and health equity.
  • The 2023 algorithm supplements AACE's 2022 Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan .
  • The AACE 2023 Comprehensive Type 2 Diabetes Management Algorithm is available online .

Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream

Retrieved on: 
Monday, May 1, 2023
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Inflammation, Medicine, RAD, Dermatitis, COVID-19, Atopic dermatitis, Acne, Back pain, IGA, Poster, Patient, Common, SE, FRCPC, Itch, Autoimmunity, AD, Upper respiratory tract infection, Headache, Research, Conference, Pharmaceutical industry, Incyte

These data were featured in a poster presentation (Poster #396) at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washington, D.C.

Key Points: 
  • These data were featured in a poster presentation (Poster #396) at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washington, D.C.
  • Results showed that patients with AD treated with Opzelura experienced a rapid and substantial improvement in itch, which was sustained and further improved through 28 days of treatment.
  • "We are pleased that the SCRATCH-AD results further emphasize the rapid impact of Opzelura on itch reduction and reinforce its profile as an effective, well-tolerated topical non-steroidal treatment for AD."
  • “I am encouraged by these results showing rapid and substantial itch reduction among AD patients treated with Opzelura, and its potential to quickly alleviate this burdensome symptom for patients.”

ASDS Partners with La Roche-Posay to Offer a Unique Mentorship Program for New Dermatologists

Retrieved on: 
Tuesday, April 18, 2023
ASDS, Dermatology, FRCPC, Travel, Partnership, La Roche-Posay, MD, Society, Practice management

Schaumburg, IL, April 18, 2023 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery (ASDS) is pleased to announce its partnership with La Roche-Posay for the 2023 Preceptorship Program, providing an avenue for dermatology residents and early-career dermatologists to expand their skills while gaining practice management insights during a short visit to the practice of an established dermatologic surgeon mentor.

Key Points: 
  • Schaumburg, IL, April 18, 2023 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery (ASDS) is pleased to announce its partnership with La Roche-Posay for the 2023 Preceptorship Program, providing an avenue for dermatology residents and early-career dermatologists to expand their skills while gaining practice management insights during a short visit to the practice of an established dermatologic surgeon mentor.
  • “The generous support of La Roche-Posay will offset travel expenses for up to 50 preceptees this year, allowing them a unique, real-world experience with invaluable lessons on core skills, new procedures and practice management — something that can’t be obtained through virtual courses and webinars,” said ASDS President Vince Bertucci, MD, FRCPC.
  • “ASDS is committed to nurturing growth of the next generation of dermatologists, and a key component to this development is the opportunity to witness a more experienced dermatologic surgeon in action, gaining knowledge that is not taught in residency, such as witnessing patient discussions, interacting with other staff and observing the practice atmosphere.”
    Preceptees can choose from over 75 tenured dermatologists across the United States for a short visit, typically three to five days.
  • During their visit, participants can:
    Specify a targeted area(s) of training, including:

Changes in Infant Emotion Regulation Following Maternal Treatment for Postpartum Depression - A Free Webinar from the Brain & Behavior Research Foundation

Retrieved on: 
Wednesday, April 5, 2023
Interim, Cognitive behavioral therapy, McMaster University, Prenatal development, Core, Bronowski Institute of Behavioural Neuroscience, DSM-IV codes, EST, Emotion, Brain & Behavior Research Foundation, MD, Associate, Mother, Canada Research Chair, Brain, Risk, Harold E. Jones Child Study Center, Psychiatry, FRCPC, Postgraduate education, Mental health, Nursing, Neuroscience, Infant

New York, April 05, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Changes in Infant Emotion Regulation Following Maternal Treatment for Postpartum Depression” on Tuesday, April 11, 2023, at 2:00 pm EST.

Key Points: 
  • New York, April 05, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Changes in Infant Emotion Regulation Following Maternal Treatment for Postpartum Depression” on Tuesday, April 11, 2023, at 2:00 pm EST.
  • Postpartum depression affects up to 1 in 5 mothers and is associated with elevated rates of emotional, behavioral, and cognitive problems in offspring.
  • It may have particularly negative effects on infant emotion regulation - the ability to modify emotions in the service of future goals.
  • The webinar is hosted by Jeffrey Borenstein, M.D., President & CEO of the Brain & Behavior Research Foundation, and host of the public television series Healthy Minds.

Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial

Retrieved on: 
Monday, April 3, 2023
Pancreatic cancer, Endoscopy, Partnership, Medical school, Alpha Sigma Tau, Pancreatic tumor, Jewish General Hospital, Alpha, Neoplasm, JGH, Breast, Brain, Research, Radiation therapy, Assistant, Lung, Therapeutic endoscopy, HIV disease progression rates, Patient, General Hospital, Division, Translational research, McGill University, CA19-9, FRCPC, Rollcage Stage II, Vulva, III, Safety, Metastasis, Disease, Medical imaging, Cancer, MD, Gastroenterology, Medicine

JERUSALEM, April 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with advanced inoperable pancreatic cancer has been treated in a feasibility and safety study of Alpha DaRT at the Jewish General Hospital (“JGH”) in Montreal, Canada, which is an affiliated teaching hospital of McGill University, Faculty of Medicine.

Key Points: 
  • The study will primarily examine the safety and feasibility of placing the Alpha DaRT sources in the tumor utilizing endoscopic ultrasound, and the overall safety of the procedure by measuring adverse events.
  • With the Alpha DaRT technology and our expertise in developing novel advanced endoscopic techniques, we are thrilled to offer patients with inoperable advanced pancreatic cancer an innovative therapeutic option.
  • We hope that the Alpha DaRT treatment will offer better outcomes to these patients with such a challenging disease.
  • We appreciate the unconditional support from Alpha Tau and the MCTRC who worked together to eliminate any barriers for opening this trial at our hospital and for securing a straightforward procedure for Alpha DaRT insertion into the pancreatic tumor.”

Notice of Compliance issued regarding Rezurock(TM) (belumosudil tablets)

Retrieved on: 
Tuesday, March 21, 2023
Faculty, GVHD, Mouth, MDCM, Eye, Quality of life, Esophagus, Inflammation, Lung, Harvard Medical School, Dana–Farber Cancer Institute, Fibrosis, Assistant professor, Medical director, MD, Patient, Division, Outline of health sciences, Disease, McGill University, Liver, FRCPC, Health, MPH, Health Canada, McGill University Faculty of Medicine and Health Sciences, Skin, Pharmaceutical industry, Dentistry, Hematology, Sanofi, Medicine

This includes fibrosis, which can have a devastating impact on a patient's health and well-being.

Key Points: 
  • This includes fibrosis, which can have a devastating impact on a patient's health and well-being.
  • I welcome the approval of Rezurock™ in Canada because it brings a new treatment option to patients who are experiencing severe and life-threatening symptoms."
  • It was developed specifically for the treatment of chronic graft-versus-host disease and it has anti-fibrotic properties.
  • The availability of Rezurock™ represents an advancement for patients who have undergone a stem cell transplant and require treatment for chronic graft-versus-host disease."

Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer

Retrieved on: 
Thursday, March 16, 2023
DSM-IV codes, LGG, Hospital for Sick Children (Toronto), Diarrhea, Progression-free survival, McKesson Corporation, Clinical trial, Hope, BRAF, Mutation, Research, Brain, Abdominal pain, PFS, BRAF V600, Lung, Rash, ASCO, Vomiting, Bleeding, Dizziness, American Society of Clinical Oncology, Novartis, MD, Patient, Melanoma, The Hospital, Annual general meeting, Nausea, St Saviour's and St Olave's Church of England School, FRCPC, Upper respiratory tract infection, Phase, FDA, Fever, Headache, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Thyroid cancer, ORR, Food, Fatigue, Medical imaging, Pharmaceutical industry, Dabrafenib

The FDA also approved liquid formulations of Tafinlar and Mekinist, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one year of age.

Key Points: 
  • The FDA also approved liquid formulations of Tafinlar and Mekinist, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one year of age.
  • These approvals make Tafinlar + Mekinist the first and only approved combination targeted therapy to treat pediatric patients with BRAF V600E LGG.
  • BRAF V600 mutations are present in 15-20% of pediatric LGGs and are associated with poor survival outcomes and less favorable response to chemotherapy4.
  • BRAF mutations have been identified as drivers of cancer growth across a wide range of solid tumors, and often have limited treatment options4,5.

Kardium Announces First Patients Treated in PULSAR IDE Study of Globe® Pulsed Field System

Retrieved on: 
Wednesday, March 15, 2023
Health, Clinical Trials, Medical Devices, Atrial fibrillation, Heart, Sale, PFA, Health Canada, Mount Sinai Hospital (Manhattan), Trial of the century, PULSE, Czech Republic, Patient, FRCPC, AF, McGill University Health Centre, Food and Drug Administration, FDA, Mount Sinai Hospital, PVI, Gold, Electrode, Safety, Femoral vein, McGill University, IDE, Inc., Food, Associate professor, Medical device, Nursing, MD, Globe

Kardium Inc. , a private medical device company that has developed the Globe® PF System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today that the first patients have been successfully treated in its PULSAR clinical study.

Key Points: 
  • Kardium Inc. , a private medical device company that has developed the Globe® PF System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today that the first patients have been successfully treated in its PULSAR clinical study.
  • The PULSAR study will enroll over 400 patients for treatment at up to 35 sites in the United States, Canada, and Europe.
  • The study expands on the successful Globe System first-in-human trial (PULSE-EU) of 69 patients.
  • “The PULSAR study will expand our knowledge in the exciting and rapidly developing field of PF.”
    “The whole team at Kardium is thrilled to be starting the PULSAR study,” said Kardium CEO Kevin Chaplin.

CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada

Retrieved on: 
Wednesday, March 8, 2023
MD, BioCryst Pharmaceuticals, PARK, Health Canada, Patient, CADTH, Disease, Hereditary angioedema, FRCPC, British Society of Cinematographers, HAE, CDEC, RESEARCH, Pharmaceutical industry, Health insurance

RESEARCH TRIANGLE PARK, N.C., March 08, 2023 (GLOBE NEWSWIRE) --  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive recommendation for ORLADEYO® (berotralstat) to be reimbursed for the routine prevention of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older.

Key Points: 
  • In issuing this positive recommendation, CADTH is opening the door to many Canadian HAE patients being able to access ORLADEYO,” said Stephen Betschel, HBSc, MD, FRCPC, FAAAAI, Chair of the Canadian Hereditary Angioedema Network.
  • “BioCryst is delighted that ORLADEYO has received this positive recommendation from CADTH.
  • Health Canada authorized ORLADEYO in June 2022 for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older.
  • The full CADTH reimbursement recommendation for ORLADEYO is available on CADTH’s website .